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Existing prognostic indices (PI) for malignant pleural mesothelioma (MPM) do not 30 
incorporate the recent advances in oncology care. The purpose of this study was to 31 
provide a PI for overall survival (OS) in MPM patients treated with chemotherapy with 32 
pemetrexed (PEM) or best supportive care (BSC) in the recent clinical setting. 33 
Methods 34 
A retrospective cohort study was performed in two hospitals in Japan (2007 - 2013).  35 
The primary outcomes were OS. The Cox proportional hazards model was used for 36 
multivariable analyses to identify prognostic factors. A final model was chosen based on 37 
both clinical and statistical significance. 38 
Results 39 
A total of 283 patients (CTx: n=228, BSC: n=55) were enrolled in the study. On 40 
multivariate analysis, regimen including platinum plus PEM, a performance status > 0, 41 
non-epithelial histological type, and stage IV disease predicted poor OS in CTx patients. 42 
As hazard ratios of individual risk factors were approximately similar, a prognostic 43 
index for OS was constructed by counting the risk factors. Median OS in CTx patients 44 
decreased by each 1-point increase in this count: 1030 days for zero; 658 days for one;  45 
 4 
 
373 days for two; 327 days for three; 125 days for four. Internal validation using the 46 
bootstrapping technique showed robustness of the model (c-index, 0.677; 95% 47 
Confidence Interval [CI], 0.624-0.729). Further, the discrimination was consistent in 48 
BSC patients (c-index, 0.799; 95% CI, 0.725-0.874). 49 
Conclusions 50 
This novel index can provide clinicians and MPM patients with a better framework for 51 
discussing prognosis at the time of diagnosis. 52 
 53 
A mini-abstract: 54 
We developed a new prognostic index for malignant pleural mesothelioma. The index 55 
reflects the recent real-world data. The index showed better discrimination than 56 
previous index. 57 
 58 
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Malignant pleural mesothelioma (MPM) used to be a rare malignancy of the 64 
mesothelium. In recent years, the incidence of this disease has increased, and this trend 65 
will likely continue worldwide over the next decade (1).  66 
Despite recent advancements in treatment, surgery, radiotherapy and chemotherapy or 67 
multimodality therapy has not be proven to be curative (2–4) . For the majority of 68 
patients, treatment options are limited to palliative chemotherapy and best supportive 69 
care (BSC)  (5). 70 
In oncologic palliative care, early determinations of prognosis play an important role in 71 
guiding end-of-life care and efforts designed to improve patients’ quality of life (6, 7). 72 
To determine the prognosis of patients with MPM, four prognostic indices (PI) have 73 
been developed; one by the Cancer and Leukaemia Group B (CALGB) (8), and three by 74 
the European Organization for Research and Treatment of Cancer (EORTC) (9–11). 75 
While the first two PIs from EORTC can indicate either a favorable or an unfavorable 76 
outcome, neither can predict the duration of survival, which means both are impractical 77 
when discussing life expectancy with a patient. The CALGB PI is complex to use, 78 
because it has various cutoffs to consider. Above all, these PIs are based on clinical trial 79 
data and may not be applicable to the clinical setting. Further, they do not incorporate 80 
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information regarding pemetrexed, which can improve overall survival (OS), and does 81 
not incorporate recent advancements in supportive care (3, 12–14). Therefore, while 82 
existing PIs might be useful for researchers in deciding which patients to include in 83 
clinical trials, these systems are less useful for clinicians who need to discuss prognoses 84 
with their MPM patients. 85 
The purpose of this study was to provide a new PI for OS in MPM patients who 86 
underwent treatment with pemetrexed or best supportive care in a recent clinical setting. 87 
 88 
Materials and methods 89 
Study design and patients 90 
A retrospective cohort study was performed, covering the period between April 1st, 2007 91 
and March 31st, 2013. The cohort was defined as all patients with histologically proven 92 
(15) MPM at either one of two tertiary hospitals that serve the South Hanshin medical 93 
region, which is an area of high MPM incidence area in Japan (16).  94 
Patients who had more than one cancer, underwent autopsy, or who received palliative 95 
chemotherapy without pemetrexed were excluded, Because our purpose is to develop a 96 
new PI in MPM patients who underwent treatment with pemetrexed which is the 97 
“standard of care” (5). Patients who had received chemotherapy or radiotherapy before 98 
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diagnosis, trimodal therapy, or surgical therapy extra-pleural pneumonectomy or 99 
pleurectomy or decortication) were excluded to avoid confounding influences (17). 100 
 101 
Definitions of prognostic variables 102 
Potential prognostic factors that were analyzed included: histological subtypes (15), 103 
International Mesothelioma Interest Group stage (18), chemotherapy regimen, age, 104 
gender, Eastern Cooperative Oncology Group performance status (PS) (19), subjective 105 
symptoms, smoking history, asbestos exposure history, comorbidities (Charlson score 106 
(20)) and baseline blood or effusion parameters at the time of diagnosis. 107 
 108 
Primary outcomes measurement 109 
The primary outcome endpoint was OS, as defined by the length of time from the date 110 
of diagnosis to death. Patients who had not died or who were lost to follow-up were 111 
censored when they were last known to be alive before September 1st, 2013. 112 
 113 
Statistical analyses 114 
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We developed the PI in those who were treated with chemotherapy to minimize the bias 115 
due to confounding by indication (21). We also evaluated the applicability of the PI in 116 
those that received BSC.  117 
In derivation, step continuous and nominal prognostic variables were dichotomized 118 
according to previous studies (8, 9, 11, 21–27). OS was estimated using the 119 
Kaplan–Meier method. The log-rank tests for each prognostic factor were used for 120 
univariate analyses. The Cox proportional hazards model was used for multivariate 121 
analyses. The Akaike’s information criterion (AIC), Schwartz’s Bayesian information 122 
criterion (BIC), and Harrell’s c index (c-index) were used for the discrimination of the 123 
model. A final model was chosen based on both clinical and statistical significance. We 124 
compared the discrimination of our index with the EORTC prognostic index (9) and the 125 
progression-free index of EORTC (11). 126 
Calibration curves showing agreement between observed and predicted outcomes over a 127 
range of predicted probabilities were drawn. We also drew Cox-Snell residuals and 128 
measured Moreau, O'Quigley, and Lellouch statistics (28). We drew log-log hazards 129 
curves and tested the proportional hazard assumption. The bootstrapping technique was 130 
used for the internal validation (for 500 replications (29)). 131 
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We carried out sensitivity analysis using multiple imputation for variants with clinically 132 
significance. Two-sided p values < 0.05 were considered to indicate statistical 133 
significance. We used Stata® ver. 13.0 (Stata Corp., College Station, TX). 134 
 135 
Ethical considerations 136 
This study was performed according to the Declaration of Helsinki and the Ethical 137 
Guidelines for Epidemiological Research by the Japanese Ministry of Health, Labour 138 
and Welfare. The protocol for the study was approved by the Ethics Committee of 139 
Kyoto University Graduate School and Faculty of Medicine (E1883). The protocol was 140 
registered in the University Hospital Medical Information Network Clinical Trials 141 
Registry with the number: UMIN000011733. 142 
 143 
Results 144 
This study included 228 patients who were treated with chemotherapy with pemetrexed 145 
and 55 patients who received BSC (Figure 1). Patient characteristics are shown in Table 146 
1. Survival curves for each group are shown in the Figure 2. 147 
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The median lengths of follow-up were 345.5 days for the chemotherapy group and 250 148 
days for the BSC group. During the follow-up period, 161 patients (70.6%) died in 149 
chemotherapy group, and 40 patients (72.7%) died in the BSC group, respectively. 150 
Univariate survival analyses are also shown in Table 1. Fifteen parameters were 151 
significantly correlated with OS according to univariate analyses: asbestos exposure, PS, 152 
dyspnea, anorexia, chest pain, body weight (BW) loss, fever, histological type, Stage, 153 
Regimen, white blood cell (WBC), platelet (Plt) count, C-reactive protein (CRP), 154 
Lactate dehydrogenase (LDH), and cytokeratin-19 fragment (CYFRA). 155 
Because of the theoretical collinearity of symptom variables, we chose only PS with 156 
respect to clinical relevance. We repeated the multivariate analysis while analyzing 157 
WBC, Plt, and CRP, separately, because of the collinearity of inflammatory variables. 158 
The discrimination for PS, Asbestos Exposure, Histology, Stage, Regimen, LDH, and 159 
CYFRA were 823 (AIC), 844 (BIC), and 0.714 (c-index). The discrimination for seven 160 
variables with WBC were 821 (AIC), 845 (BIC), and 0.726 (c-index). The 161 
discrimination for six variables with CRP were 825 (AIC), 849 (BIC), and 0.715 162 
(c-index). The discrimination for six variables with Plt were 824 (AIC), 848 (BIC), and 163 
0.711 (c-index). We entered WBC into a stepwise backward Cox proportional hazards 164 
model (Table 2). PS, histology, stage, and regimen remained significant after the 165 
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multivariate analysis. Hazard ratios of individual risk factors were 1.82-2.25. Therefore, 166 
a PI for the OS was constructed using a simple count of the number of risk factors 167 
(Table 3). The median OS of each category is shown in Table 4.   168 
We calculated the discrimination of the rPHS (regimen, PS, Histology, or Stage) index. 169 
The c-index was 0.677. After 500 bootstrap replications from the original patients, the 170 
95% confidence interval (CI) of the c-index of the PHS score was 0.624-0.729.  171 
We calculated the c-index for the EORTC prognostic index (9), which was 0.569. The 172 
difference between the two indices persisted after bootstrap replications (0.108; 95%CI, 173 
0.053-0.163). We also calculated the c-index for the progression-free index of the 174 
EORTC (11), which was 0.552. The difference between the two indices persisted after 175 
bootstrap replications (0.125, 95%CI, 0.082-0.166).   176 
There was good calibration of the model, with close agreement between observed and 177 
predicted OS (Figure S1), and also with close agreement between Cox-Snell residuals 178 
and the 45-degree slope (Figure S2). The Moreau, O'Quigley, and Lellouch test showed 179 
that the model fit of the Cox regression model was adequate (p = 0.38). 180 
We drew log-log hazards curves for the CTx group which were parallel (Figure S3). The 181 
p value of the test for the proportional hazard assumption was 0.07. 182 
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We carried out sensitivity analysis using multiple imputation to create and analyze 10 183 
multiply imputed datasets. We imputed only PS with regards to clinical significance. 184 
These estimates and their standard errors were combined using Rubin’s rules (30). The 185 
results showed consistency (Table 4). The discrimination was also consistent in the BSC 186 
group (c-index, 0.799; 95%CI, 0.725-0.874).  187 
 188 
Discussion 189 
We developed a new PI for patients with MPM that predicts median OS, incorporates 190 
pemetrexed information, and incorporates recent advancements in supportive care in the 191 
normal clinical setting. The rPHS index is obtained by a simple count of the risk factors 192 
(regimen including platinum plus PEM, PS>0, non-epithelial histology, and stage>3). 193 
The index can stratify patients into four different prognostic groups with different 194 
median survivals. The index has good discrimination for those treated with pemetrexed 195 
group as well as those treated with BSC. 196 
Patients with advanced cancer often want to know their prognosis (31). One study (32) 197 
reported that patients with advanced cancer have an overwhelming preference for an 198 
opportunity to prepare for the end of life. They want to know that their families are 199 
prepared for their death, which often includes having finances in order, and for patients, 200 
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having funeral arrangements planned. They want to have the opportunity to resolve 201 
unfinished business, remember personal accomplishments, and to say goodbye to 202 
important people. In order to allow these patients to direct their energies to these matters, 203 
it is important to provide them with accurate information regarding their prognosis. In 204 
fact, early palliative care, including early accurate perceptions of prognosis, has 205 
improved the quality of life and possibly the OS of patients with advanced cancer (6). 206 
We believe that the present findings will influence the usual care of MPM patients for 207 
several reasons. When one patient diagnosed with MPM and decided to treat with 208 
pemetrexed-regimen, the patient and their physician can discuss based on the 209 
median OS of the rPHS index. Without the index we discussed the prognosis based 210 
on the median survival time from the trial or the cohort study. Our PI consists of 211 
variables frequently used in usual care of MPM patients. Indeed, PS, histology, and 212 
stage are well-known prognostic factors in previous studies (8–11, 33) and are 213 
components of the evaluation at the time of initial diagnosis (34). Further, our PI can be 214 
calculated easily by simple counting; calculators are not necessary, and our PI has more 215 
discriminatory power than the EORTC PI (9), which is one of the best-known clinical 216 
PIs. We note that the distribution of median age and OS were different when comparing 217 
previous reports (8–11) and our CTx cohort; our study included more elderly patients 218 
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(67.7 versus 58-62 years), and our study included patients with relatively better 219 
prognoses (11.5 versus 5-12.6 months). The cohort of our study ensures the 220 
generalizability of the findings, because the two hospitals cover the South Hanshin 221 
medical region and any patients with MPM in this region will visit one of these two 222 
hospitals. So, the participants in the present study are a good representation of patients 223 
with MPM. We included only patients with histologically proven MPM and not those 224 
with only cytologically proven MPM. Because there is morphologic overlap between 225 
benign reactive mesothelial cells and malignant cells of mesothelioma (15), it is not 226 
recommended to make a diagnosis of mesothelioma based on cytology alone (34). We 227 
think that this restriction ensured our study result. 228 
Our cohort consisted of patients treated with BSC. For the small number of BSC 229 
participants we didn’t develop another index for BSC patients, but validated PHS index.  230 
The discrimination was good (c-index, 0.799; 95% CI, 0.725-0.874). No previous study 231 
has validated a PI in patients treated with BSC. This information will be useful for 232 
discussions regarding prognosis between clinicians and their patients.  233 
Since 1998, several PIs have been described. In contrast to our PHS index, other PIs 234 
were based on clinical trial data. Therefore, in the context of usual care, our PHS index 235 
might be more widely applicable than other PIs. We cannot compare our PI with the PI 236 
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of Bottomley (23) because we did not evaluate patients with the EORTC LC13 or 237 
QLQ-C30. Their PI’s c-index was 0.66. The point estimation was similar to that of our 238 
PI. Pass (27) reported stage, histology, sex, age, treatment, adjuvant treatment, platelets 239 
and WBC are clinical prognostic factor except for PS. We think this discrepancy may 240 
reflect the difference of target population. We excluded those received surgery, but 241 
Pass’s target population is those received either palliative or potentially curative surgery. 242 
There are several limitations in the study. First, this was a retrospective study with a 243 
substantial number of missing PS data, so we performed sensitivity analysis using 244 
multiple imputation. The result confirms the robustness of our model. Second, we were 245 
not able to know the reason why each patient treated with the modality because this is a 246 
retrospective study and treatment allocations were not protocol based. To clarify the 247 
preferences for treatment in MPM patients prospective qualitative and quantitative 248 
studies will be needed (36). But this limitation reflects the normal clinical setting. Third, 249 
we assessed internal validation with the bootstrap method, but the sample size of this 250 
study did not allow for external validation, so validation studies are needed. 251 
We developed a new PI using PS, histology, and stage for MPM patients treated with 252 
chemotherapy or BSC. This PI will allow better discussion between clinicians and 253 
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patients with regards to prognosis. Further prospective studies using this PI are 254 
warranted.  255 
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  BSC 
(n = 228), N (%) (days) 95%CI p value (n=55), n (%) 
Age (years) 
 mean±SD 
67.7±8.2    74.5±9.6 
Age (years)        
75> 181 (79.4) 512 375-562 0.2000  24 (43.6) 
75≤ 47 (20.6) 366 190-441  31 (56.4) 
Gender               
Female 39 (17.1) 514 314-699 0.4700  13 (23.6) 
Male 189 (82.9) 432 359-524  42 (76.4) 
Smoke            
Never 65 (30.0) 524 366-624 0.4100  19 (38.0) 
Current / Ever 152 (70.0) 425 327-524  31 (62.0) 
Missing 11    5 
Charlson 
comorbidity index    
     
<2 205 (89.9) 461 372-533 0.5100  42 (76.4) 
2≤ 23 (10.1) 366 224-1213  13 (23.6) 
Asbestos exposure       
          No 28 (12.4) 710 327-1213 0.0480   
Yes 197 (87.6) 397 353-511  14 (26.4) 
       Missing 3    39 (73.6) 
PS                2 
0 37 (22.4) 926 524-1372 0.0014    
1≤ 128 (77.6) 434 362-562  19 (41.3) 
     Missing 63    37 (58.7) 
Dyspnea                9 
No 52 (33.8) 658 524-1030 0.0003  13 (31.7) 
Yes 102 (66.2) 425 319-512  28 (68.3) 
     Missing 74    14 
Anorexia                 
           No 145 (82.4) 524 432-654 0.0001  29 (55.8) 
 2 
 
Yes 31 (17.6) 296 166-373  23 (44.2) 
     Missing 52    3 
Chest pain               
           No 58 (39.2) 648 511-926 0.0007  16 (43.2) 
Yes 90 (60.8) 353 263-432  21 (56.8) 
      Missing 80    18 
BW loss                  
           No 96 (70.7) 566 512-804 0.0001  20 (60.6) 
Yes 41 (30.0) 299 177-425  13 (39.4) 
     Missing 91    22 
Fever             
           No 92 (76.7) 524 397-648 0.0280  38 (92.7) 
 Yes 28 (23.3) 353 223-518  3 (7.3) 
      Missing 108    14 
Histological type      
Epithelial 149 (65.4) 545 493-640 0.0000  17 (30.9) 
Non-epithelial 79 (34.7) 277 221-330  38 (69.1) 
Stage       
I-III 133 (58.3) 549 461-658 0.0000  30 (54.5) 
           IV 95 (41.7) 327 242-375  25 (45.5) 
Regimen      
Platinum plus PEM 205 (89.9) 221 373-547 0.0007  
PEM monotherapy 23 (10.1) 499 86-425   
WBC (/μl)                  
8300> 160 (70.5) 512 391-598 0.0400  36 (65.5) 
8300≤ 67 (29.5) 359 238-501  19 (34.5) 
Missing 1      
Neutro/lymph         
5> 182 (82.4) 445 368-549 0.0600  35 (64.8) 
5≤ 39 (17.7) 362 188-514  19 (35.2) 
Missing 7    1 
Hb (g/dL)                   
10≤ 218 (96) 445 372-544 0.0700  45 (81.8) 
10> 9 (4.0) 224 66-526  10 (18.2) 
Missing 1      
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Plt (10^5/μl)             
40> 188 (82.8) 461 373-549 0.0100  42 (76.4) 
40≤ 39 (17.2) 327 176-526  13 (23.6) 
Missing 1      
ALP (IU/l)                  
Abnormal 32 (14.9) 397 228-562 0.93 0 (0.0) 
 Normal 183 (85.1) 441 362-544  53 (100.0) 
Missing             13    2 
LDH (IU/L)                 
Abnormal 26 (11.6) 493 375-544 0.011 11 (20.4) 
 Normal 198 (88.4) 242 87-603  43 (79.6) 
Missing 4    1 
CRP (mg/dl)              
5> 189 (83.3) 461 373-549 0.0076  40 (72.7) 
 5≤ 38 (16.7) 359 167-518  15 (27.3) 
Missing         1      
CEA (ng/ml)               
5> 200 (94.3) 338 156-NE 0.7800  45 (95.7) 
5≤ 12 (5.7) 441 366-526  2 (4.3) 
Missing 16    8 
CYFRA (ng/ml)          
3.5> 162 (75) 512 375-598 0.0090  22 (48.9) 
3.5≤ 54 (25) 368 242-445  23 (51.1) 
Missing 12    10 
Pleural  glucose 
(mg/dl)     
     
40> 21(22.3) 511 156-710 0.2200  10 (30.3) 
40≤ 73(77.7) 373 319-547  23 (69.7) 
Missing 134    22 
Abbreviations: N, number; OS, overall survival; SD, standard deviation; CI,  
confidence interval; BSC, best supprotive care; PS, Eastern Cooperative Oncology 
Group performance status; BW, body weight; PEM, pemetrexed; WBC, white blood 
cell; Neutro, neutrocyte; Lymph, lymphocyte; Hb, hemoglobin; Plt, platelet; ALP, 
alkaly phosphatase; LDH, lactate dehydrogenase; CRP, C-reactive protein; CEA,  
carcinoembryonic antigen; CYFRA, cytokeratin-19 fragment. 
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Table 2 Backward Cox proportional hazards model 
Clinical factors HR 95%CI 
PS        
0 
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I-III 
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Abbreviations: HR, hazard ratio; CI, confidence 
interval; PS, Eastern Cooperative Oncology Group 
performance status; LDH, lactate dehydrogenase; 






Table 3 Final model  
Clinical factors HR 95% CI Score 
PS        
0 





















Stage     
I-III 




















Abbreviations: HR, hazard ratio; CI, confidence interval; PS, Eastern 




Table 4 The rPHS index for overall survival (sensitivity analysis) 
 Chemotherapy Best supportive care 
Score N Median OS 
(days) 






































rPHS index = (if platinum + PEM 0, otherwise 1) + (if PS 0<, otherwise 0) + (if Histology non-epithelial, 
otherwise 0) + (if Stage=4, otherwise 0)  
Abbreviations: N, number; OS, overall survival; CI, confidence interval; NE, not estimable; PS, Eastern 































Histologically proven in one 
of two hospitals 
N=397 
Trimodal therapy N=54 
Surgery N= 20 
Chemotherapy without 
pemetrexed N=6 
Double cancer N=9 
Treated with chemotherapy, or 
radiotherapy before diagnosis N=8 
Autopsy N=6 





Chemotherapy with pemetrexed 
N=228 
 Cisplatin plus PEM N=168 
  Carboplatin plus PEM N=37 





Figure 2 Survival curve (days)  
 
Abbreviations: BSC, best supportive care; 
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